Electrochemotherapy in the treatment of cutaneous malignancy: Outcomes and subgroup analysis from the cumulative results from the pan-European International Network for Sharing Practice in Electrochemotherapy database for 2482 lesions in 987 patients (2008-2019)
Electrochemotherapy in the treatment of cutaneous malignancy: Outcomes and subgroup analysis from the cumulative results from the pan-European International Network for Sharing Practice in Electrochemotherapy database for 2482 lesions in 987 patients (2008-2019)
复制标题
DOI：
10.1016/j.ejca.2020.06.020
复制
发表时间：
2020-10-01
影响因子：
8.4
通讯作者：
Gehl, J.
中科院分区：
文献类型：
--
作者：
Clover, A. J. P.;de Terlizzi, F.;Gehl, J.
背景：电化学疗法（ECT）是一种治疗原发性和继发性皮肤肿瘤的方法。ECT组的国际网络共享实践研究ECT后使用一个共同的数据库与定义的parameters.Methods的治疗结果：28个中心在欧洲前瞻性地上传数据超过11年的时间。反应率进行了调查有关的初步诊断，肿瘤大小，选择的电极类型，博来霉素给药途径，电参数记录和以前的照射在treated field.Results：九百八十七例，2482肿瘤病变被纳入分析。总缓解率（OR）为85%（完全缓解率[CR]：70%，部分缓解率：15%，疾病稳定率：11%，疾病进展率：2%）。对于不同组织学类型，恶性黑色素瘤转移的OR和CR率分别为82%和64%，基底细胞癌分别为96%和85%，乳腺癌转移分别为77%和62%，鳞状细胞癌分别为80%和63%，卡波西肉瘤分别为98%和91%。不同组织类型之间的差异（p < 0.0001）和治疗的病变大小一致（直径为3 cm时二分）（p < 0.0001）。六角形电极通常用于较大的肿瘤，但对于高达3 cm的肿瘤，线性阵列电极比六角形电极提供更好的肿瘤控制（80%：74%，p < 0.003）。对于大于2 cm的肿瘤，静脉给药优于肿瘤内（IT）给药（p < 0.05）。上级。记录的电流因肿瘤组织学和大小而异，但不影响缓解率。在以前照射过的地区，响应选择性较低IT administration.Conclusions：这些累积的数据赞同ECT在广泛的组织类型的效率。对2482个病灶的分析详细介绍了治疗反应的亚组分析，为未来的治疗选择提供了信息。(C)2020由Elsevier Ltd.出版
Background: Electrochemotherapy (ECT) is a treatment for both primary and secondary cutaneous tumours. The international Network for sharing practices on ECT group investigates treatment outcomes after ECT using a common database with defined parameters.Methods: Twenty-eight centres across Europe prospectively uploaded data over an 11-year period. Response rates were investigated in relation to primary diagnosis, tumour size, choice of electrode type, route of bleomycin administration, electrical parameters recorded and previous irradiation in the treated field.Results: Nine hundred eighty-seven patients, with 2482 tumour lesions were included in analysis. The overall response (OR) rate was 85% (complete response [CR]: 70%, partial response rate: 15%, stable disease: 11%, and progressive disease: 2%). For different histologies, OR and CR rates for metastases of malignant melanoma were 82% and 64%, basal cell carcinoma were 96% and 85%, breast cancer metastases were 77% and 62%, squamous cell carcinoma were 80% and 63% as well as Kaposi's sarcoma were 98% and 91%, respectively. Variance was demonstrated across histotypes (p < 0.0001) and in accordance with size of lesion treated (dichotomised at diameter of 3 cm (p < 0.0001). Hexagonal electrodes were generally used for larger tumours, but for tumours up to 3 cm, linear array electrodes provided better tumour control than hexagonal electrodes (80%:74%, p < 0.003). For tumours more than 2 cm, intravenous administration was superior to intratumoural (IT) administration (p < 0.05). Current recorded varied across tumour histologies and size but did not influence response rate. In previously irradiated areas, responses were selectively lower for IT administration.Conclusions: These cumulative data endorse efficiency of ECT across a broad range of histotypes. Analysis of 2482 lesions details subgroup analysis on treatment response informing future treatment choices. (C) 2020 Published by Elsevier Ltd.